ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors

Exclusion Criteria

• •Any of the following would exclude the subject from participation in the study:
• •1. Treatment with any of the following:
• •Previous or current treatment with B7-H3 targeted therapy. Any cytotoxic chemotherapy, investigational agents and anticancer drugs within 14 days prior to the first scheduled dose of HS-20093. Prior treatment with a monoclonal antibody within 28 days prior to the first scheduled dose of HS-20093.
• •Radiotherapy with a limited field of radiation for palliation within 2 weeks, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to the first scheduled dose of HS-20093.
• •Pleural or peritoneal effusion requiring clinical intervention. Pericardial effusion.
• •Major surgery within 4 weeks prior to the first scheduled dose of HS-20093. Spinal cord compression or brain metastases. Treatment with drugs that are predominantly strong inhibitors or inducers or sensitive substrates of CYP3A4, CYP2D6, P-gp or BCRP with a narrow therapeutic range within 7 days of the first dose of study drug; or requiring treatment with these drugs during the study.
• •Currently receiving drugs known to prolong QT interval or may cause torsade de pointe; or requiring treatment with these drugs during the study
• •2. Patients with BRCA and ATM mutation.
• •3. Any unresolved toxicities from prior therapy greater than Grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE) 5.0 with the exception of alopecia or neurotoxicity
• •4. History of other primary malignancies.
• •5. Inadequate bone marrow reserve or organ dysfunction.
• •6. Evidence of cardiovascular risk.
• •7. Severe, uncontrolled or active cardiovascular diseases.
• •8. Severe or uncontrolled diabetes, including diabetes ketoacidosis or hyperglycemia hypertonic occurring within 6 months before the first dose of the study drug, or the glycosylated hemoglobin value ≥ 7.5% in the screening period.
• •9. Severe or poorly controlled hypertension.
• •10. Bleeding symptoms with apparent clinical significance or obvious bleeding tendency within 1 months prior to the first dose of HS-20093
• •11. Serious arteriovenous thrombosis events occurred within 3 months before the first dose
• •12. Severe infections occurred within 4 weeks before the first dose
• •13. Patients who have received continuous steroid treatment for more than 30 days within 30 days before the first dose, or need long-term (≥ 30 days) steroid treatment, or who have other acquired and congenital immunodeficiency diseases, or have a history of organ transplantation
• •14. The presence of active infectious diseases before the first dose such as hepatitis B, hepatitis C, tuberculosis, syphilis, or human immunodeficiency virus HIV infection, etc.
• •15. Hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh Grade B or more severe cirrhosis
• •16. Other moderate or severe urinary diseases that may interfere with the detection or treatment of drug-related urinary toxicity or may seriously affect urinary function.
• •17. History of serious neuropathy or mental disorders.
• •18. Women who are breastfeeding or pregnant or planned to be pregnant during the study period.
• •19. Vaccination or hypersensitivity of any level within 4 weeks prior to the first dose of HS-20093
• •20. History of severe hypersensitivity reaction, severe infusion reaction or allergy to recombinant human or mouse derived proteins
• •21. Hypersensitivity to any ingredient of HS-20093
• •22. Unlikely to comply with study procedures, restrictions, and requirements in the opinion of the investigator.
• •23. Any disease or condition that, in the opinion of the investigator, would compromise subject safety or interfere with study assessments.